ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine,

Slides:

Advertisements

Similar presentations

Where we stand in diabetes field ?

Advertisements

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.

Comparing Medications for Adults With Type 2 Diabetes

Practical Considerations in Clinical Management. Guideline-recommended glycemic targets in diabetes A1C (%) FPG (mg/dL) Postprandial glucose (mg/dL) ADA

The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

Type 2 Diabetes Mellitus Therapeutics in Major Developed Markets to Strong Pipeline and Expanding Treatment Population to Encourage Robust Growth.

Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Insulin Therapy for Type 2 Diabetes Mellitus JAMA.

What's New in Basal Insulin for Diabetes

Medications Used in the Treatment of Diabetes Mellitus

Copyright © 2015 by the American Osteopathic Association.

Copyright © 2015 by the American Osteopathic Association.

Case-Based Examination of Treatment Options in Type 2 Diabetes Management.

Copyright © 2015 by the American Osteopathic Association.

Diabetes and Ramadan: Practical guidelines

NATURAL HISTORY OF BETA CELL FAILURE IN T2DM

James Thrasher, MD The American Journal of Medicine

From: Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 DiabetesA Systematic Review and Meta-analysis Ann Intern Med.

Position Statement for People with Types 1 and 2 Diabetes Who Fast during Ramadan Harpreet Singh Bajaj MD, MPH, FACE; Tyceer Abouhassan BEd, MD, MBA,

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

Stuart A. Ross, MB CHB, FRACP, FRCP(C)

ADA-Standard of Medical Care-2017 Updates to standards of medical care in diabetes 2016 Diabetes Care 2017;40(Suppl. 1):S1–S138.

Special Consideration in Insulin Therapy

Figure 4 Amino acid structure of short-acting and long-acting insulins

Global Projections for Diabetes:

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Insulin Innovation.

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Diabetes management (Updated guidelines)

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use David M. Kendall, MD, Robert M. Cuddihy, MD,

Emerging CVOT Data and Clinical Application

GLP-1 Receptor Agonists: How Early Is Appropriate?

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

James Thrasher, MD The American Journal of Medicine

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations

Insulin Innovation.

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Predicted and observed HbA1c levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Approach to starting and adjusting insulin in type 2 diabetes.

Insulin Innovation.

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Figure 3 Pharmacodynamic action profiles of long-acting insulins

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Figure 1 Sites of action of glucose-lowering agents

Predicted and observed BMI levels using doubly robust estimation adjusting for either a comprehensive set of confounders (left panel) or a set of confounders.

Evolution of Insulin: From Human to Analog

ADA/EASD general recommendations for type 2 diabetes management (1).

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

Glycaemic management of type 2 diabetes

IGlarLixi SoloSTAR pen device and dose delivery of insulin glargine (units) and lixisenatide (µg) ranging from 15 units insulin glargine/5 µg lixisenatide.

Glucose-lowering medication in type 2 diabetes: overall approach.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Oral hypoglycemics Jennifer R Marks, MD.

Antihyperglycemic therapy in adults with type 2 diabetes

An insulin simplification regimen: from multiple injections to once-daily long-acting (basal) insulin plus noninsulin agents. *Basal insulins: glargine.

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Glucagon-Like Peptide-1 Receptor (GLP-1R) Agonists and Dipeptidyl Peptidase-4 (DPP-4) Inhibitors: How Do They Exert Their Metabolic Actions? Part 5.

Presentation transcript:

ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine, detemir, or degludec). ADA type 2 diabetes glycemic control algorithm, reproduced with permission from ref. 4. *Usually a basal insulin (neutral protamine Hagedorn, glargine, detemir, or degludec). DDP-4, dipeptidyl peptidase-4; DPP-4-i, DPP-4 inhibitor; fxs, fractures; GI, gastrointestinal; GLP-1 RA, GLP-1 receptor agonist; GU, genitourinary; HF, heart failure; hypo, hypoglycemia; SGLT2, sodium–glucose cotransporter 2; SGLT2-i, SGLT-2 inhibitor; SU, sulfonylurea; TZD, thiazolidinedione. Debbie Hinnen, and Jodi Strong Diabetes Spectr 2018;31:145-154 ©2018 by American Diabetes Association